SAMSARA NETWORKS INC. SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 19th, 2021 • Samsara Inc. • Services-computer integrated systems design • California
Contract Type FiledNovember 19th, 2021 Company Industry JurisdictionThis Seventh Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of January 13, 2021 by and among Samsara Networks Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser (as defined in that certain Extension Series F Preferred Stock Purchase Agreement, dated as of May 15, 2020, by and among the Company and certain of the Investors (the “Purchase Agreement”)) that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
APPLOVIN CORPORATION INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 22nd, 2021 • Applovin Corp • Services-computer programming, data processing, etc. • Delaware
Contract Type FiledMarch 22nd, 2021 Company Industry JurisdictionThis Investors’ Rights Agreement (this “Agreement”) is made and entered into as of August 15, 2018 by and among Applovin Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder,” and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
EX-4.2 4 d892618dex42.htm INVESTORS' RIGHTS AGREEMENT Execution Version AUDENTES THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors' Rights Agreement • May 5th, 2020 • California
Contract Type FiledMay 5th, 2020 JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 8, 2015 by and among Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any subsequent investor that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
ELANCE-ODESK, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 4th, 2018 • Upwork Inc. • Services-computer processing & data preparation • California
Contract Type FiledJune 4th, 2018 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of August 19, 2014, by and among Elance-oDesk, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A-1 hereto (each of which is referred to in this Agreement as an “ Investor”), each of the holders of Common Stock listed on Schedule B hereto (each of which is referred to in this Agreement as a “Common Holder”), and each holder of a Lender Warrant (as defined below) listed on Schedule A-2 hereto (each of which is referred to in this Agreement as a “Lender”).
AUDENTES THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJanuary 4th, 2016 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 8, 2015 by and among Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any subsequent investor that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
AUDENTES THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 6th, 2015 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledNovember 6th, 2015 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 8, 2015 by and among Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any subsequent investor that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
LOXO ONCOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 30th, 2014 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of April 24, 2014 by and among Loxo Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
LOXO ONCOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 14th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 14th, 2014 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of April 24, 2014 by and among Loxo Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.